Lidocaine ointment has many uses, including the treatment of minor burns, scrapes, and bug bites. As a result, the market is anticipated to increase over the projected period. It is also used to prevent and relieve pain during specific procedures, such as cosmetic surgery and dental surgery. Thus, it is anticipated that the market would increase throughout the forecast period because to the rising popularity of cosmetic procedures. In addition, surgical treatments rose by 54% in 2021, with the average American plastic surgeon performing 320 operations, up from 220 in the previous year. Throughout the forecast period, market growth is anticipated to be driven by increased technical activity for the formulation of lidocaine ointment. For instance, a 5% concentration of glycerol monostearate (GMS) aids in the penetration of lidocaine deep into the dermis, according to a National Library of Medicine paper from September 2021. The release of lidocaine from the ointment was made easier by the self-nanoemulsifying properties of GMS. In order to enhance the formulation of the local anaesthetic lidocaine ointment, self-nanoemulsification of GMS has been used.
Coherent Market Insights estimates that the market for Lidocaine Ointment is anticipated to reach US$ 1,275.2 million in 2022 and grow at a CAGR of 7.7% during the following five years (2022-2030).
Market Leaders in the Lidocaine Ointment Industry:
Glenmark Pharmaceuticals U.S. Inc.
The corporate headquarters are in Mumbai, where it was founded in 1977. The company manufactures both a generic medication and an active pharmaceutical ingredient. Under the brand name FabiFlu, the company launched favipiravir, a potential COVID-19 treatment, in India in June 2020. In March 2023, Glenmark Pharma's generic antibiotic medication wins USFDA approval.
Teligent Inc.
The company was established in 1996 and its main office is in New Jersey, United States. Creams, ointments, injections, and other medical supplies are available from the company, which also manufactures and distributes pharmaceutical goods. The company's goal is to dominate the market for specialty generic prescription drugs.
Taro Pharmaceutical Industries Ltd.
The company was established in 1959 and is situated in Hawthorne, New York, United States. The organisation is a global, science-based pharmaceutical firm that develops, produces, and sells healthcare products. Prescription and over-the-counter medicines are among the items offered by the company. Taro Pharma announced in July 2020 that it will pay $8.2 million to purchase Aquinox Pharmaceutical in Canada.